UNH
Bearish signalScored 2026-10-19 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
UnitedHealth Group Incorporated
- Nom
- UnitedHealth Group Incorporated
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NYSE
- Capitalisation
- $378.7B
- Employés
- 390,000
- PDG
- Stephen J. Hemsley
- Site web
- https://www.unitedhealthgroup.com
- Marché
- ALHCCICNCCVSELVHUM
UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services. It facilitates access to networks of specialist care providers, offers health management programs, direct care delivery, consumer engagement initiatives, and financial services. Its diverse clientele includes individuals (served directly through care systems), employers, insurance payers, and government organizations. Optum Insight specializes in providing technology, information, and consulting services to the healthcare industry. Its offerings include software and data products, advisory consulting arrangements, and outsourced managed services. Clients span hospital systems, physicians, health plans, governmental bodies, life sciences companies, and other relevant organizations. Finally, Optum Rx handles the company's pharmaceutical care services. This segment manages retail pharmacy networks, provides home prescription delivery, and offers specialty and compounding pharmacy capabilities. Leveraging its purchasing power and clinical expertise, Optum Rx also develops advanced programs related to step therapy, formulary management, medication adherence, and integrated disease and drug therapy management. UnitedHealth Group Incorporated, founded in 1977, has its corporate headquarters located in Minnetonka, Minnesota.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$660,910
Avg sell (VWAP, 90d window) $395.99 vs last close $410.70 (+3.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Liquidity
- Liquid $2,482,979,073/day · 20d vol
- Last synced
-
2026-10-26 21:11:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-21 | Conway Patrick Hugh | Sell · S | 1,169 | $390.00 | $455,910 | Form 4 |
| 2026-08-05 | Conway Patrick Hugh | Sell · S | 500 | $410.00 | $205,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2025-04-16 | John Boozman | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | Sale | $1,001 - $15,000 |
| 2026-09-23 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2026-09-10 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2026-07-30 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2026-07-10 | Daniel Milton Newhouse | Sale (Full) | $1,001 - $15,000 |
| 2026-06-12 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2026-06-04 | Maria Elvira Salazar | Sale (Full) | $1,001 - $15,000 |
| 2026-04-22 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-04-14 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-03-19 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2026-03-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-02-20 | Chuck Fleischmann | Purchase | $15,001 - $50,000 |
| 2026-02-10 | Gilbert Cisneros | Sale | $15,001 - $50,000 |
| 2026-02-05 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-12-23 | Kevin Hern | Sale (Full) | $250,001 - $500,000 |
| 2025-12-19 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-05 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2025-11-04 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-18 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2025-09-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2025-09-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-28 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2025-08-15 | Tim Moore | Sale | $50,001 - $100,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-13 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-08-08 | Tim Moore | Purchase | $15,001 - $50,000 |
| 2025-08-05 | Gilbert Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2025-08-04 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-08-01 | Tim Moore | Purchase | $1,001 - $15,000 |
| 2025-07-24 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-21 | Tim Moore | Purchase | $1,001 - $15,000 |
| 2025-07-16 | Tim Moore | Purchase | $15,001 - $50,000 |
| 2025-06-24 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-27 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-05-20 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2025-05-16 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-05-16 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-05-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-05-14 | David Taylor | Sale (Full) | $15,001 - $50,000 |
| 2025-05-14 | David Taylor | Sale (Full) | $1,001 - $15,000 |
| 2025-05-14 | Marjorie Taylor Greene | Purchase | $15,001 - $50,000 |
| 2025-05-08 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-06 | Val Hoyle | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2025-04-29 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-24 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-04-22 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-15 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2025-04-11 | Daniel Milton Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-10 | John J. McGuire | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-04-07 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-31 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-31 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-03-27 | Greg Landsman | Sale (Full) | $15,001 - $50,000 |
| 2025-03-13 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-26 | Gilbert Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-02-24 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-01-24 | Val Hoyle | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-24 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-01-14 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2025-01-13 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-01-09 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2025-01-07 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2024-11-19 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-11-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-05-03 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-05-03 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-04-12 | Mike Kelly | Sale (Full) | $1,001 - $15,000 |
| 2024-03-25 | Michael T. McCaul | Exchange | $250,001 - $500,000 |
| 2024-02-13 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-03-15 | Rich McCormick | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-19 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
UNH's strong earnings catalyst (beat Q3, raised guidance, +6.3% share reaction) provides meaningful near-term momentum, but the deeply stressed financial health scores (liquidity 35, fundamentals trend 25) reflect…
The first sentence of the analysis written for UNH on 2026-10-19 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Pulls against a bullish reading. Current ratio 0.79 · operating margin 4.2%
Suggested stop 391.05, nearest stored support minus 0.5 ATR(4.8% under the last close). Reward/risk to the next stored resistance is 0.47. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
- 2026-10-19 4.6 Million Americans Leave Health Insurance Market in Biggest Exodus in a Decade — and Those Staying Face a 15% Rate Hike More than 4.6 million Americans left the individual health insurance market in a single year. New research from KFF shows enrollment fell 18%, from 25.2 million in June 2025 to 20.5 million in June 2026.
- 2026-10-19 Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings UnitedHealth''s Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks.
- 2026-10-19 3.2 Million Seniors Will Lose Their Medicare Advantage Plans in 2027 — and Their Replacement Options Are Shrinking Retirement planning gets harder when healthcare coverage becomes a moving target. A familiar insurance card can mean access to trusted doctors, predictable prescription costs, and benefits that help stretch a fixed income.
- 2026-10-19 Is UnitedHealth Group Stock a Buy After Another Solid Quarter? UnitedHealth''s Q3 earnings numbers soared past expectations. The healthcare company also raised its guidance for the full year.
- 2026-10-19 What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs As the midterm election approaches, investors may try to anticipate how different potential outcomes could impact the market. After two years of unified control by the Republican party, polls and analysis are predicting a divided government, with at least one of the chambers of Congress controlled by Democrats beginning in 2027.
- 2026-10-19 UnitedHealth: My Thesis Has Played Out, I Wouldn''t Chase Here (Rating Downgrade) UnitedHealth Group is downgraded from strong buy to buy as shares appear fully valued at a 20x forward P/E. Q3 earnings beat estimates, with revenue of $112.7B and EPS of $4.69; management raised 2026 adjusted EPS guidance to at least $20.50. Operational execution, AI-driven efficiencies, and long-term growth targets of 13%-16% underpin upside potential, but valuation and operating risks warrant caution.
- 2026-10-17 UnitedHealth: 3 Key Takeaways for Long-Term Investors AI chart summarization expanded to 40% of clinicians, cutting review time by 33%. UnitedHealth will reduce total prior authorizations by 30% by year end.
- 2026-10-17 If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys These funds can help you weather any storm that might be on the way.
- 2026-10-17 UnitedHealth Group Incorporated $UNH Holdings Boosted by Annex Advisory Services LLC Annex Advisory Services LLC grew its holdings in UnitedHealth Group Incorporated (NYSE: UNH) by 70.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,856 shares of the healthcare conglomerate''s stock after purchasing an additional 48,279 shares during the period.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 18.5% | 22.3% | 24.5% | 24.6% | 24.2% | |
| Ebit Margin | 4.2% | 6.0% | 8.7% | 8.8% | 8.3% | |
| Ebitda Margin | 5.2% | 7.0% | 9.8% | 9.8% | 9.4% | |
| Operating Profit Margin | 4.2% | 8.1% | 8.7% | 8.8% | 8.3% | |
| Pretax Profit Margin | 3.3% | 5.0% | 7.8% | 8.1% | 7.8% | |
| Continuous Operations Profit Margin | 2.9% | 3.8% | 6.2% | 6.4% | 6.2% | |
| Net Profit Margin | 2.7% | 3.6% | 6.0% | 6.2% | 6.0% | |
| Bottom Line Profit Margin | 2.7% | 3.6% | 6.0% | 6.2% | 6.0% | |
| Current Ratio | 0.788 | 0.827 | 0.792 | 0.774 | 0.789 | |
| Quick Ratio | 0.788 | 0.827 | 0.792 | 0.774 | 0.789 | |
| Solvency Ratio | 0.079 | 0.095 | 0.151 | 0.148 | 0.150 | |
| Cash Ratio | 0.212 | 0.244 | 0.257 | 0.262 | 0.273 | |
| Price To Earnings Ratio | 24.952 | 32.344 | 22.361 | 24.614 | 27.394 | |
| Price To Earnings Growth Ratio | -1.619 | -0.920 | 1.867 | 1.406 | 2.176 | |
| Forward Price To Earnings Growth Ratio | -1.619 | -0.920 | 1.867 | 1.406 | 2.176 | |
| Price To Earnings Diluted Ratio | 24.952 | 32.615 | 22.604 | 25.032 | 27.773 | |
| Price To Earnings Diluted Growth Ratio | -1.697 | -0.932 | 1.786 | 1.460 | 2.172 | |
| Price To Book Ratio | 3.192 | 5.072 | 5.639 | 6.367 | 6.599 | |
| Price To Sales Ratio | 0.671 | 1.174 | 1.347 | 1.528 | 1.646 | |
| Price To Free Cash Flow Ratio | 18.687 | 22.697 | 19.489 | 21.158 | 23.808 | |
| Price To Operating Cash Flow Ratio | 15.251 | 19.416 | 17.219 | 18.896 | 21.193 | |
| Debt To Assets Ratio | 0.253 | 0.258 | 0.246 | 0.235 | 0.217 | |
| Debt To Equity Ratio | 0.833 | 0.830 | 0.760 | 0.741 | 0.641 | |
| Debt To Capital Ratio | 0.454 | 0.454 | 0.432 | 0.426 | 0.391 | |
| Long Term Debt To Capital Ratio | 0.435 | 0.438 | 0.396 | 0.412 | 0.371 | |
| Financial Leverage Ratio | 3.290 | 3.219 | 3.084 | 3.159 | 2.957 | |
| Working Capital Turnover Ratio | -21.159 | -20.736 | -18.223 | -17.665 | -16.324 | |
| Operating Cash Flow Ratio | 0.171 | 0.233 | 0.293 | 0.294 | 0.285 | |
| Operating Cash Flow Sales Ratio | 0.044 | 0.060 | 0.078 | 0.081 | 0.078 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.816 | 0.855 | 0.884 | 0.893 | 0.890 | |
| Debt Service Coverage Ratio | 2.102 | 2.751 | 3.548 | 5.023 | 4.260 | |
| Interest Coverage Ratio | 4.739 | 8.266 | 9.969 | 13.592 | 14.440 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.246 | 5.325 | 5.472 | 8.426 | 6.172 | |
| Operating Cash Flow Coverage Ratio | 0.251 | 0.315 | 0.431 | 0.455 | 0.486 | |
| Capital Expenditure Coverage Ratio | 5.438 | 6.917 | 8.585 | 9.353 | 9.105 | |
| Dividend Paid And Capex Coverage Ratio | 1.707 | 2.194 | 2.865 | 2.980 | 2.889 | |
| Dividend Payout Ratio | 0.657 | 0.523 | 0.302 | 0.298 | 0.305 | |
| Enterprise Value Multiple | 15.370 | 18.576 | 14.933 | 16.631 | 18.400 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 18.5% | ▼-3.8% | ▼-4.3% |
| Ebit Margin | 4.2% | ▼-1.8% | ▼-3.0% |
| Ebitda Margin | 5.1% | ▼-1.9% | ▼-3.1% |
| Operating Profit Margin | 4.2% | ▼-3.8% | ▼-3.4% |
| Pretax Profit Margin | 3.3% | ▼-1.7% | ▼-3.1% |
| Continuous Operations Profit Margin | 2.9% | ▼-0.9% | ▼-2.2% |
| Net Profit Margin | 2.7% | ▼-0.9% | ▼-2.2% |
| Bottom Line Profit Margin | 2.7% | ▼-0.9% | ▼-2.2% |
| Current Ratio | 0.788 | ▼-0.038 | ▼-0.006 |
| Quick Ratio | 0.788 | ▼-0.038 | ▼-0.006 |
| Solvency Ratio | 0.079 | ▼-0.016 | ▼-0.045 |
| Cash Ratio | 0.212 | ▼-0.032 | ▼-0.037 |
| Price To Earnings Ratio | 24.952 | ▼-7.392 | ▼-1.381 |
| Price To Earnings Growth Ratio | -1.619 | ▼-0.699 | ▼-2.201 |
| Forward Price To Earnings Growth Ratio | -1.619 | ▼-0.699 | ▼-2.201 |
| Price To Earnings Diluted Ratio | 24.952 | ▼-7.663 | ▼-1.644 |
| Price To Earnings Diluted Growth Ratio | -1.697 | ▼-0.765 | ▼-2.255 |
| Price To Book Ratio | 3.192 | ▼-1.880 | ▼-2.182 |
| Price To Sales Ratio | 0.671 | ▼-0.503 | ▼-0.602 |
| Price To Free Cash Flow Ratio | 18.687 | ▼-4.010 | ▼-2.481 |
| Price To Operating Cash Flow Ratio | 15.251 | ▼-4.165 | ▼-3.144 |
| Debt To Assets Ratio | 0.253 | ▼-0.005 | ▲0.011 |
| Debt To Equity Ratio | 0.833 | ▲0.003 | ▲0.072 |
| Debt To Capital Ratio | 0.454 | ▲0.001 | ▲0.023 |
| Long Term Debt To Capital Ratio | 0.434 | ▼-0.004 | ▲0.024 |
| Financial Leverage Ratio | 3.290 | ▲0.070 | ▲0.148 |
| Working Capital Turnover Ratio | -21.159 | ▼-0.423 | ▼-2.338 |
| Operating Cash Flow Ratio | 0.171 | ▼-0.062 | ▼-0.084 |
| Operating Cash Flow Sales Ratio | 0.044 | ▼-0.017 | ▼-0.024 |
| Free Cash Flow Operating Cash Flow Ratio | 0.816 | ▼-0.039 | ▼-0.051 |
| Debt Service Coverage Ratio | 2.102 | ▼-0.649 | ▼-1.435 |
| Interest Coverage Ratio | 4.739 | ▼-3.527 | ▼-5.462 |
| Short Term Operating Cash Flow Coverage Ratio | 3.245 | ▼-2.080 | ▼-2.483 |
| Operating Cash Flow Coverage Ratio | 0.251 | ▼-0.064 | ▼-0.136 |
| Capital Expenditure Coverage Ratio | 5.438 | ▼-1.479 | ▼-2.441 |
| Dividend Paid And Capex Coverage Ratio | 1.707 | ▼-0.487 | ▼-0.820 |
| Dividend Payout Ratio | 0.657 | ▲0.134 | ▲0.240 |
| Enterprise Value Multiple | 15.370 | ▼-3.206 | ▼-1.412 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $300.40B | $469.94B | $500.51B | $495.19B | $473.52B | |
| Enterprise value | $354.42B | $521.54B | $542.52B | $529.45B | $498.15B | |
| EV / Sales | 0.79x | 1.30x | 1.46x | 1.63x | 1.73x | |
| EV / Op. cash flow | 17.99x | 21.55x | 18.66x | 20.20x | 22.30x | |
| EV / Free cash flow | 22.05x | 25.19x | 21.12x | 22.62x | 25.05x | |
| EV / EBITDA | 15.37x | 18.58x | 14.93x | 16.63x | 18.40x | |
| Net debt / EBITDA | 2.34x | 1.84x | 1.16x | 1.08x | 0.91x | |
| Current ratio | 0.79x | 0.83x | 0.79x | 0.77x | 0.79x | |
| Income quality | 1.54x | 1.59x | 1.30x | 1.30x | 1.29x | |
| Graham number | $176 | $187 | $228 | $201 | $177 | |
| Graham net-net | -$154 | -$140 | -$125 | -$116 | -$96 | |
| Tax burden | 82.0% | 71.8% | 76.9% | 76.4% | 77.5% | |
| Interest burden | 78.6% | 83.7% | 90.0% | 92.6% | 93.1% | |
| Working capital | -$24.32B | -$17.99B | -$20.62B | -$20.17B | -$16.53B | |
| Invested capital | $117.42B | $122.56B | $109.76B | $97.71B | $78.27B | |
| Return on assets | 3.9% | 4.8% | 8.2% | 8.2% | 8.1% | |
| Operating ROA | 6.2% | 11.3% | 12.5% | 12.4% | 11.7% | |
| Return on tangible assets | 6.7% | 8.6% | 14.5% | 14.6% | 13.7% | |
| Return on equity | 12.8% | 15.5% | 25.2% | 25.9% | 24.1% | |
| Return on invested capital | 8.2% | 12.3% | 14.3% | 14.0% | 13.9% | |
| Return on capital employed | 9.7% | 16.6% | 18.5% | 18.2% | 17.9% | |
| Earnings yield | 4.0% | 3.1% | 4.5% | 4.1% | 3.7% | |
| Free cash flow yield | 5.4% | 4.4% | 5.1% | 4.7% | 4.2% | |
| Capex / Op. cash flow | 18.4% | 14.5% | 11.6% | 10.7% | 11.0% | |
| Capex / Depreciation | 83.1% | 85.4% | 85.2% | 82.4% | 79.1% | |
| Capex / Sales | 0.8% | 0.9% | 0.9% | 0.9% | 0.9% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | |
| Intangibles / Total assets | 42.3% | 43.6% | 43.4% | 43.9% | 40.5% | |
| Days sales outstanding | 43d | 44d | 38d | 34d | 36d | |
| Days payables outstanding | 77d | 80d | 42d | 85d | 82d | |
| Operating cycle | 43d | 44d | 38d | 34d | 36d | |
| Cash conversion cycle | -34d | -36d | -3d | -50d | -47d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years